Aligos Therapeutics, Inc.: capital expenditure payments
Capital expenditure payments for Aligos Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Aligos Therapeutics, Inc. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2024-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-01-01 | 2024-12-31 | 130,000 | USD | 2025-03-10 | 10-K · 0000950170-25-035929 |
| 2023-01-01 | 2023-12-31 | 19,000 | USD | 2025-03-10 | 10-K · 0000950170-25-035929 |
| 2022-01-01 | 2022-12-31 | 943,000 | USD | 2024-03-12 | 10-K · 0000950170-24-029953 |
| 2021-01-01 | 2021-12-31 | 892,000 | USD | 2023-03-09 | 10-K · 0000950170-23-007033 |
| 2020-01-01 | 2020-12-31 | 2,064,000 | USD | 2022-03-10 | 10-K · 0000950170-22-003365 |
| 2019-01-01 | 2019-12-31 | 2,786,000 | USD | 2021-03-23 | 10-K · 0001564590-21-014872 |
Related financial histories
- Aligos Therapeutics, Inc.: total assets
- Aligos Therapeutics, Inc.: total liabilities
- Aligos Therapeutics, Inc.: stockholders equity
- Aligos Therapeutics, Inc.: cash and cash equivalents
- Aligos Therapeutics, Inc.: net income or loss
- Aligos Therapeutics, Inc.: operating cash flow
- Aligos Therapeutics, Inc.: contract revenue excluding tax
- Aligos Therapeutics, Inc.: financing cash flow
- Aligos Therapeutics, Inc.: investing cash flow
- Aligos Therapeutics, Inc.: retained earnings or deficit
- Aligos Therapeutics, Inc.: basic weighted-average shares
- Aligos Therapeutics, Inc.: diluted weighted-average shares
- Aligos Therapeutics, Inc.: basic earnings per share
- Aligos Therapeutics, Inc.: diluted earnings per share
- Aligos Therapeutics, Inc.: income tax expense or benefit
- Aligos Therapeutics, Inc.: net property, plant and equipment
- Aligos Therapeutics, Inc.: share-based compensation expense
- Aligos Therapeutics, Inc.: operating income or loss
- Aligos Therapeutics, Inc.: current assets
- Aligos Therapeutics, Inc.: current liabilities
- Aligos Therapeutics, Inc.: current accounts payable
- Aligos Therapeutics, Inc.: operating expenses
- Aligos Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Aligos Therapeutics, Inc. / CIK 0001799448
- Captured
- 2026-09-21T17:27:54.999Z
- SEC response SHA-256
4c3e53deed4dd94480ece54ac10c5eae71197d15f4e20bc3098e0d1eb4831e09
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001799448.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))